Vés al contingut

Molecular Determinants of Cancer Therapy Resistance

18 nov. 24
- 20 nov. 24

Targeting tumor cell signaling and proliferation is a major strategy in classical and novel cancer  therapies. Multiple cytotoxic and targeted drugs aim to prevent cancer cell proliferation or to  eliminate cells undergoing DNA replication or mitosis. Despite the initial success of these  strategies, resistance mechanisms are common, especially in patients with metastatic disease.  Beyond cancer cell autonomous mechanisms, there is good evidence that cells from the tumor  stroma can also contribute to therapy resistance. 

This 42nd edition of the Biomed conferences will bring basic and translational scientists together  with clinicians to discuss the latest findings on how tumors respond to therapies and develop  resistance, as well the challenges of monitoring therapy resistance in the clinic and finding  effective therapeutic strategies.  

Topics will include mechanistic studies, genetic analysis, evolutionary dynamics and the  contribution of the tumor microenvironment, as well as new approaches to monitoring and  tackling therapy resistance in the clinic. We strive to create a highly focused think‐tank  atmosphere for a select group of attendees to concentrate on the challenges of understanding  resistance mechanisms and finding novel therapeutic strategies. 

Imatge

Presentation

Conference organizers

Imatge
Dr Angel R Nebreda

Dr. Angel R. Nebreda
IRB Barcelona/ICREA
Barcelona, Spain

Dr. Clare M. Isacke
ICR
London, UK

Imatge

Dr. Marcos Malumbres
VHIO/ICREA
Barcelona, Spain

 

There is no registration fee for this conference, but the number of participants is limited, with a number of seats saved for IRB Barcelona alumni. Previous registration is required.

Priority will be given to those who submit the highest quality abstracts for short talks or posters and the order of registration will be considered. 

Abstracts should include a title, authors, affiliations, summary (max 250 words) and references

Dates importants

REGISTRATION DEADLINE: 1 OCTOBER, 2024

(Note: Any issue about the registration or abstract, please contact: meritxell.gavalda@irbbarcelona.org)

Programme

Monday, 18 November

8.30 Registration

9.00 Welcome by Dr. Francesc Posas (IRB Barcelona, Director) and organizers (Dr. Angel R. Nebreda, Dr. Clare M. Isacke and Dr. Marcos Malumbres)

Session I: Mechanisms of resistance to chemotherapy and targeted therapies (I) 
Chair: Dr. Clare M. Isacke, ICR (London, UK)

9.15 Mechanisms of resistance to PARP inhibition in breast cancer

Dr. Violeta Serra, VHIO (Barcelona, Spain)

9.45 Not all BRCA2 variants are created equal with respect to PARP inhibitor sensitivity and resistance

Dr. Aura Carreira, CBMSO (Madrid, Spain)

10.15 Short talk 1: Increased expression of ABCG2 (BCRP) promotes adaptive resistance to niraparib in novel clinically relevant models of treatment resistant ovarian cancer

Caitlin Macdonald, University of Dundee (Dundee, UK)

10.30 - 11.30 Coffee break and poster session

11.30 Quiescence as a mechanism of resistance to CDK4/6 inhibitors

Dr. Alexis Barr, MRC London Institute of Medical Sciences (London, UK)

12.00 Cell cycle rewiring as a mechanism of resistance to CDK-targeted therapies

Dr. Marcos Malumbres, VHIO/ICREA (Barcelona, Spain)

12.30 Short talk 2: CDK4 Inhibition Modulates Apoptosis Resistance and Metabolic Responsiveness in Triple-Negative Breast Cancer Cells

Dr. Lluis Fajas, University of Lausanne (Lausanne, Switzerland)

12.45 Short talk 3: High-throughput Identification of Novel Modulators of the ALT Pathway

Dr. Travis H. Stracker, NCI (Bethesda, MD, USA)

13.00 Short talk 4: Loss of SLFN11 confers replication stress tolerance in ATRX deficient ALT cancers

Dr. Sandra Segura-Bayona, The Francis Crick Institute (London, UK)

13.15 - 14.45 Lunch and poster session

Session II: Mechanisms of resistance to chemotherapy and targeted therapies (II) 
Chair: Dr. Alexis Barr, MRC London Institute of Medical Sciences (London, UK)

14.45 Exploring tumor vulnerabilities by targeting stress kinase signaling

Dr. Angel R. Nebreda, IRB Barcelona/ICREA (Barcelona, Spain)

15.15 Short talk 5: Activation of the Integrated Stress Response to overcome multidrug resistance in cancer therapy

Jorge Mota-Pino, CNIO (Madrid, Spain)

15.30 Short talk 6: Mechanical stress promotes chemotherapy resistance through autophagy activation in pancreatic cancer

Dr. Maria Kalli, University of Cyprus (Nicosia, Cyprus)

15.45 - 16.30 Coffe break and poster session

16.30 The one-two-punch approach in cancer therapy. Trying to discover the second punch

Dr. Óscar Fernández-Capetillo, CNIO (Madrid, Spain)

17.00 Short talk 7: EZH2 Inhibitors Create a Dependency on YAP for Survival in HER2+ Breast Cancers

Dr. Naiara Perurena, Brigham and Women's Hospital and Harvard Medical School (Boston, MA,  USA)

17.15 Short talk 8: LARP1-Mediated Drug Tolerance in Colorectal Cancer: A Non-Genetic Mechanism Underlying Chemoresistance and Tumor Relapse

Dr. Pedro Fuentes, IDIBELL (Barcelona, Spain)

17.30 Metabolic challenges and therapeutic opportunities in pancreatic cancer

Dr. Nada Y. Kalaany, Harvard Medical School- Boston Children's Hospital (Boston, MA, USA)

18.00 End of session

19.30 Speakers Tapas dinner 

 

Tuesday, 19 November

Session III: Tumor cell non-autonomous mechanisms in therapy resistance 
Chair: Angel R. Nebreda, IRB Barcelona/ICREA (Barcelona, Spain)

9.00 Targeting the tumour microenvironment

Dr. Clare M. Isacke, ICR (London, UK)

9.30 Understanding Mechanisms of Microenvironment-Mediated Therapy Resistance

Dr. Michael T. Hemann, Koch Institute for Integrative Cancer Research at MIT (Cambridge, MA, USA)

10.00 Short talk 9: A TGFβ-enriched senescent secretome triggered by platinum therapy promotes lung and ovarian cancer resistance

Dr. Daniel Muñoz-Espín, Early Cancer Institute, University of Cambridge (Cambridge, UK)

10.15 - 11.15 Coffee break and poster session

11.15 Perivascular macrophages influence the response to chemotherapeutics in cancer

Dr. James Arnold, King's College London (London, UK)

11.45 Immune cells induced ECM remodeling and their clinical implications

Dr. Yuval Shaked, Technion- Israel Institute of Technology (Haifa, Israel)

12.15 Short talk 10: Apoptotic protection in therapy-induced senescent melanoma cells is mediated through BCL-xL binding to BAK

Dr. Joan Montero, UB (Barcelona, Spain)

12.30 Short talk 11: Coordinated fragmentation confers functional properties to senescent cells

Dr. Bill Keyes, IGBMC (Strasbourg, France)

12.45 - 14.30 Lunch and poster session

14.30 Neutrophil extracellular traps formed during chemotherapy confer treatment resistance via TGF-β activation

Dr. Jean Albrengues, IRCAN (Nice, France)

15.00  Identifying alternative pathways for important cellular processes through genetics

Dr. Thijn Brummelkamp, NKI (Amsterdam, The Netherlands)

15.30 Short talk 12:  Osmotic stress as a modulator of the response to microtubule-based therapies

Dr. Guillermo de Cárcer, IIBM-CSIC (Madrid, Spain)

15.45 - 16.30 Coffee break and poster session

Session IV: Cell plasticity and Evolutionary dynamics 
Chair: Dr. Óscar Fernández-Capetillo, CNIO (Madrid, Spain)

16.30 Therapy resistance and tumor cell plasticity in colorectal cancer

Dr. Eduard Batlle, IRB Barcelona/ICREA (Barcelona, Spain)  

17.00 Deciphering phenotypic diversity and lung cancer evolution

Dr. Nicholas McGranahan, UCL (London, UK)

17.30 Short talk 13: Cancer Cell Plasticity Defines Response to Immunotherapy in Cutaneous Squamous Cell Carcinoma

Dr. Laura Lorenzo-Sanz, IDIBELL (L’Hospitalet de Llobregat, Barcelona, Spain)

17.45 Short talk 14: The nucleolus connects inflammation and tumor cell plasticity in colorectal cancer

Dr. Joffrey Pelletier, IRB Barcelona (Barcelona, Spain)

18.00 End of session

20.30 Invited Speakers dinner 

 

Wednesday, 20 November

Session V: New approaches to monitoring and tackling therapy resistance in the clinic 
Chair: Dr. Marcos Malumbres, VHIO/ICREA (Barcelona, Spain)

9.00 Immunogenomic determinants of late-stage tumors and the influence of anti-cancer therapies

Dr. Francisco Martínez-Jiménez, VHIO (Barcelona, Spain)

9.30 Short talk 15: Spatial transcriptomic analysis elucidates tissue patterns associated with PARP inhibitor resistance in high grade serous ovarian cancer patients

Kathleen Jane Imbach, Josep Carreras Leukaemia Research Institute (Badalona, Barcelona, Spain)

9.45 Short talk 16: Study and validation of the metabolic signature of extracellular vesicles as a prognostic and predictive marker in pancreatic cancer

Pilar Espiau-Romera, IIS Aragon, Hospital Universitario Miguel Servet (Zaragoza, Spain)

10.00 The day after the drug - investigating persister cells memory

Dr. Yaara Oren, TAUEX (Tel-Aviv, Israel)

10.30 - 11.30 Coffee break and poster session

11.30 Tracing back primed resistance in cancer

Dr. Anna Vähärautio, University of Helsinki (Helsinki, Finland)

12.00 How do we manage treatment resistance in Small Cell Lung Cancer in the clinic

Dr. Luis Paz-Ares, SEOM (Madrid, Spain)

12.30 Concluding remarks

12.45 End of conference

Venue

The BARCELONA BIOMED CONFERENCE Molecular Determinants of Cancer Therapy Resistance will be placed at the Casa Convalescència in the heart of Barcelona. Talks will take place in the Aula Magna.

Casa Convalescència
C/ Sant Antoni Maria Claret, 171
08041 Barcelona

Tel +34 934 335 000
https://www.uab.cat/casa-convalescencia/ 

 

 

How to reach the Casa Convalescència:

Underground
Yellow line (L4) - GUINARDÓ – HOSPITAL DE SANT PAU station
Blue line (L5) - SANT PAU – DOS DE MAIG station

By bus
Lines: 15, 19, 20, 45, 47, 50, 51, 92 and 192.

For the GPS
Introduce the following coordinates:
Latitude: 41.413702 (41° 24' 49.33'' N)
Longitude: 2.177482 (2° 10' 38.94'' E)

From the airport

* Train + Underground. At the RENFE station, take the train to Sants-Estació. Once there take the Underground's blue line (L5) till SANT PAU – DOS DE MAIG station.
* Bus + Underground. Outside the airport terminal, take the AEROBUS to Plaça Catalunya. Walk one corner till Plaça Urquinaona and take the Underground's yellow line (L4) to GUINARDÓ – HOSPITAL DE SANT PAU station.

Barcelona Metropolitan Transport webiste (with metro and bus maps)

 

Accomodation

Speakers will be lodged at the Hotel Catalonia Sagrada Familia
Aragó 577- 579
08026, Barcelona
Telephone: +34 93 245 89 05

www.cataloniahotels.com/en/hotel/catalonia-sagrada-familia

Other hotels
A list of additional hotels within walking distance of the Casa Convalescència can be found at: https://www.barcelona-tourist-guide.com/en/hotels/hotelmaps/eixample-right-barcelona-hotel.html
(The Casa Convalescència is located near the violet point 27/3 star). Rates will vary depending on choice of hotel and season. Please check with the hotel of your choice directly for the best offer.

Residences
Another possibility is the Lesseps Residence Hall, and is available for short-term stays.

Lesseps Residence Hall
Plaza Lesseps, 12 08023 Barcelona
View on map
Telephone: +34 933 941 600
e-mail: lesseps@resa.es
www.resa.es/en/city/barcelona

Participants registered for events in the Barcelona BioMed series should contact the hotels and residences directly to arrange bookings and payment.

Speakers

Imatge

Dr. Jean Albrengues
IRCAN (Nice, France)

Imatge

Dr. James Arnold
King's College London (London, UK)

Imatge

Dr. Eduard Batlle
IRB Barcelona/ ICREA (Barcelona, Spain)

Imatge

Dr. Alexis Barr
MRC London Institute of Medical Sciences (London, UK)

Imatge

Dr. Thijn Brummelkamp NKI (Amsterdam, The Netherlands)

Imatge

Dr. Aura Carreira
CBMSO (Madrid, Spain)

Imatge

Dr. Oskar Fernandez-Capetillo
CNIO (Madrid, Spain)

Imatge

Dr. Michael Hemann
Koch Institute for Integrative Cancer Research at MIT (Cambridge, MA, USA)

Imatge

Dr. Nada Y. Kalaany
Harvard Medical School- Boston Children's Hospital (Boston, MA, USA)

Imatge

Dr. Francisco Martínez-Jiménez VHIO (Barcelona, Spain)

Imatge

Dr. Nicholas McGranahan
UCL (London, UK)

Imatge

Dr. Yaara Oren
TAUEX (Tel-Aviv, Israel)

Imatge

Dr. Luis Paz-Ares
SEOM (Madrid, Spain)

Imatge

Dr. Violeta Serra
VHIO (Barcelona, Spain)

Imatge

Dr. Yuval Shaked
Technion- Israel Institute of Technology (Haifa, Israel)

Imatge

Dr. Anna Vähärautio
University of Helsinki (Helsinki, Finland)